Segall Bryant & Hamill LLC Invests $5.88 Million in Johnson & Johnson (NYSE:JNJ)

Segall Bryant & Hamill LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 36,303 shares of the company’s stock, valued at approximately $5,883,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Prospera Private Wealth LLC lifted its stake in shares of Johnson & Johnson by 948.6% during the 3rd quarter. Prospera Private Wealth LLC now owns 52,293 shares of the company’s stock worth $8,475,000 after buying an additional 47,306 shares during the last quarter. Premier Fund Managers Ltd acquired a new stake in Johnson & Johnson during the third quarter worth approximately $7,982,000. Kraft Davis & Associates LLC grew its position in shares of Johnson & Johnson by 12.2% in the third quarter. Kraft Davis & Associates LLC now owns 2,592 shares of the company’s stock valued at $416,000 after purchasing an additional 281 shares during the last quarter. Counterweight Ventures LLC increased its stake in shares of Johnson & Johnson by 16.3% during the third quarter. Counterweight Ventures LLC now owns 1,603 shares of the company’s stock worth $260,000 after purchasing an additional 225 shares during the period. Finally, West Family Investments Inc. boosted its position in shares of Johnson & Johnson by 13.2% in the third quarter. West Family Investments Inc. now owns 9,719 shares of the company’s stock valued at $1,575,000 after acquiring an additional 1,134 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on JNJ shares. Wells Fargo & Company boosted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Citigroup boosted their price objective on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Guggenheim raised their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Finally, Morgan Stanley upped their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.94.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.8 %

Shares of NYSE JNJ opened at $155.79 on Friday. The stock has a market cap of $375.08 billion, a P/E ratio of 22.55, a price-to-earnings-growth ratio of 2.72 and a beta of 0.53. The firm has a 50 day moving average price of $160.41 and a two-hundred day moving average price of $156.17. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.66 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson’s payout ratio is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.